Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-05-03
2011-05-03
Wen, Sharon (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S326000, C536S023530
Reexamination Certificate
active
07935502
ABSTRACT:
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.
REFERENCES:
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5997868 (1999-12-01), Goldberg et al.
patent: 6432406 (2002-08-01), Goldberg et al.
patent: 6881557 (2005-04-01), Foote
patent: 7220410 (2007-05-01), Kim et al.
patent: 7408043 (2008-08-01), Chung et al.
patent: 7459536 (2008-12-01), Cao et al.
patent: 7494650 (2009-02-01), Kim et al.
patent: 7632926 (2009-12-01), Kim et al.
patent: 7649083 (2010-01-01), Winston, Jr. et al.
patent: 7659378 (2010-02-01), Han et al.
patent: 7687063 (2010-03-01), Kim et al.
patent: 7718174 (2010-05-01), Chung et al.
patent: 2005/0118643 (2005-06-01), Burgess et al.
patent: 2007/0036797 (2007-02-01), Kim et al.
patent: 2008/0038256 (2008-02-01), Chung et al.
patent: 2009/0104192 (2009-04-01), Kim et al.
patent: 2010/0173362 (2010-07-01), Han et al.
patent: WO-01/34650 (2001-05-01), None
patent: WO-2005/017107 (2005-02-01), None
patent: WO-2005/044848 (2005-05-01), None
patent: WO-2005/107800 (2005-11-01), None
patent: WO-2006/130773 (2006-12-01), None
patent: WO-2007/115049 (2007-10-01), None
Caulfield et al. (1992) “A Pathogenic Monoclonal Antibody, G8, is Characteristic of Antierythrocyte Autoantibodies from Coombs'-Positive NZB Mice,” The Journal of Immunology 148(7):2068-2073.
Monestier et al. (1994) “Molecular Analysis of Mercury-Induced Antinucleolar Antibodies in H-2sMice,” The Journal of Immunology 152(2):667-675.
Database: GenBank, Accession No. X60424, 2004.
Database: GenBank, Accession No. X60425, 2004.
Database: GenBank, Accession No. X75096, 2006.
Australian Patent Office Search Report and Written Opinion dated Apr. 19, 2010.
Burgess et al., “Fully Human Monoclonal Antibodies to Hepatocyte Growth Factor With Therapeutic Potential Against Hepatocyte Growth Factor/C-Met-Dependent Human Tumors” (2006)Cancer Res. 66:3, pp. 1721-1729.
Burr et al., “Anti-Hepatocyte Growth Factor Antibody Inhibits Hepatocyte Proliferation During Liver Regeneration”Journal of Pathology, Chicester, Sussex, GB, vol. 185, (Jul. 1998) pp. 298-302.
Cao et al., “Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models”Proc. Natl. Acad. Sci. 2001 USA 98: 7443-7448.
Hwang et al., “Use of human germline genes in a CDR homology-based approach to antibody humanization”Methods. May 2005;36(1):35-42.
Kim et al., “Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma axenografts” (2006)Clinical Cancer Research12: 1292-1298.
R&D Systems, Inc. 1999 Catalog, p. 185, Cat. #MAB294, anti-human HGF monoclonal antibody.
Rubin et al., “Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product”Biochim Biophys Acta. Dec. 23, 1993;1155(3):357-71.
Studnicka et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues”Protein Eng. Jun. 1994;7(6):805-14.
Tan et al., “Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28J Immunol. Jul. 15, 2002;169(2):1119-25.
Zaccolo et al., “Dimerization of FAB Fragments Enables Ready Screening of Phage Antibodies that Affect Hepatocyte Growth Factor/Scatter Factor Activity on Target Cells”European Journal of Immunology, vol. 27, No. 3, (1997), pp. 618-623.
International Search Report for PCT/2007/012950 dated Apr. 15, 2008.
International Search Report for PCT/2007/012939 dated Jan. 30, 2008.
Breault Lyne
Etemad-Gilbertson Bijan
Gyuris Jeno
Han May
Knuehl Christine
AVEO Pharmaceuticals, Inc.
Goodwin & Procter LLP
Wen Sharon
LandOfFree
Hepatocyte growth factor (HGF) binding proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatocyte growth factor (HGF) binding proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatocyte growth factor (HGF) binding proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702407